Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study
Open Access
- 30 August 2018
- journal article
- research article
- Published by Hindawi Limited in Schizophrenia Research and Treatment
- Vol. 2018, 1-7
- https://doi.org/10.1155/2018/4834135
Abstract
Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.Keywords
This publication has 55 references indexed in Scilit:
- Clinical outcomes of long‐acting risperidone in recent versus long‐term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e‐STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)Early Intervention in Psychiatry, 2013
- Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophreniaSchizophrenia Research, 2012
- Review: Suicide and schizophrenia: a systematic review of rates and risk factorsJournal of Psychopharmacology, 2010
- International Consensus Study of Antipsychotic DosingAmerican Journal of Psychiatry, 2010
- Global Assessment of Functioning (GAF): properties and frontier of current knowledgeAnnals of General Psychiatry, 2010
- In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophreniaSchizophrenia Research, 2009
- Differential effects of typical and atypical antipsychotics on brain myelination in schizophreniaSchizophrenia Research, 2007
- Partial compliance with antipsychotics and its impact on patient outcomesInternational Journal of Psychiatry in Clinical Practice, 2007
- Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJournal of Psychopharmacology, 2005
- Measuring emotional intelligence with the MSCEIT V2.0.Emotion, 2003